人类免疫缺陷病毒短转录诱导物连接因子1对浸润性乳腺癌患者新辅助化疗疗效预测的临床价值分析

Clinical value of factor that binds to the inducer of short transcripts of human immunodeficiency virus-1 in predicting the efficacy of neoadjuvant chemotherapy in patients with invasive breast cancer

目的探究人类免疫缺陷病毒短转录诱导物连接因子1(FBI-1)对浸润性乳腺癌患者新辅助化疗疗效预测的临床价值。方法收集70例浸润性乳腺癌患者的临床资料,并检测肿瘤组织标本中FBI-1表达情况,以临床疗效、病理学疗效显著与非显著进行分组,采用单因素及Logsitic回归模型分析相关指标与浸润性乳腺癌新辅助化疗疗效的关系。结果新辅助化疗前,70例浸润性乳腺癌患者中49例(70.00%)为FBI-1高表达、21例(30.00%)为FBI-1低表达,化疗后,18例(25.71%)为FBI-1高表达、52例(74.29%)为FBI-1低表达,FBI-1高表达患者显著减少(P﹤0.01)。不同临床分期、淋巴结转移及孕激素受体(PR)、Ki-67、FBI-1表达情况的浸润性乳腺癌临床疗效/病理学疗效比较,差异均有统计学意义(P﹤0.05)。临床分期为Ⅲ期、淋巴结转移2~3个的浸润性乳腺癌患者肿瘤组织中FBI-1高表达率分别明显高于临床分期为Ⅱ期、淋巴结转移0~1个的患者,差异均有统计学意义(P﹤0.01)。Logistic回归分析结果显示,FBI-1及Ki-67均是浸润性乳腺癌患者临床疗效/病理学疗效的独立预测因子(P﹤0.05)。结论乳腺癌患者新辅助化疗疗效与FBI-1表达情况有关,且FBI-1为临床疗效/病理学疗效的独立预测因子,具有一定的预测价值。

Objective To explore the clinical value of factor that binds to the inducer of short transcripts of human immunodeficiency virus-1(FBI-1) in the prediction of the efficacy of neoadjuvant chemotherapy in patients with invasive breast cancer. Method The clinical data of 70 patients with invasive breast cancer were collected, and the expression of FBI-1 in these tumor tissues was detected. The participants were divided into two groups according to whether the effect of clinical response and the pathological response was significant or not. Univariate and Logistic regression models were used to analyze the relationship between the target indicators and the efficacy of neoadjuvant chemotherapy for invasive breast cancer. Result Before neoadjuvant chemotherapy, 49 cases(70.00%) of 70 invasive breast cancer patients had high FBI-1 expression, and 21 cases(30.00%) had FBI-1 low expression. After chemotherapy, 18 cases(25.71%) had FBI-1 high expression, 52 cases(74.29%) had FBI-1 low expression, and FBI-1 high expression patients were significantly reduced(P<0.01). The clinical efficacy/pathological efficacy comparisons of different clinical stages, lymph node metastasis and progesterone receptor(PR), Ki-67, FBI-1 expression in invasive breast cancer were statistically significant(P<0.05). The high expression rate of FBI-1 in tumor tissues of invasive breast cancer patients with clinical stage Ⅲ and lymph node metastasis 2-3 were significantly higher than those in patients with clinical stage Ⅱ, lymph node metastasis 0-1, and the differences were statistically significant(P<0.01). Logistic regression analysis showed that both FBI-1 and Ki-67 were independent rsk factors of clinical efficacy/pathological efficacy of patients with invasive breast cancer(P<0.05). Conclusion The efficacy of neoadjuvant chemotherapy in patients with breast cancer is closely related to the expression of FBI-1, and this target is an independent predictor of clinical and pathological efficacy with promising predictive value to some degree.